Back to Nodes
technology
NMN/NAD+ Evidence Boundary
NMN/NAD+ has real human RCT evidence but the dose-effect-population specificity is not public knowledge — this gap is the product.
72Risingmedium
STATUS active
EVIDENCE 0 records
CREATED 2026-06-20
UPDATED 2026-06-20
LongevitySupplement Evidence
Score Breakdown
Momentum
70
Evidence
68
Mispricing
65
Catalyst
62
Strategic
75
Risk Ctrl
70
Why It Matters
Most NMN marketing overstates what human evidence supports. An honest boundary map builds trust, reduces claim risk, and helps brands formulate defensible products.
Description
NMN and NAD+ precursors have attracted enormous consumer interest. Human RCT evidence exists but is highly specific to dosage, population, and endpoint. Most brands and consumers operate on extrapolated animal data. A precise evidence map would be commercially valuable.
Evidence Map (0 records)
No structured evidence attached. High confidence requires ≥2 evidence records.
Catalysts
▸Growing PubMed corpus on NMN human trials
▸Regulatory scrutiny increasing on anti-aging claims
▸Consumer intelligence increasing post-social media
Risks
▲Evidence base may shift rapidly as more trials complete
▲Brands may prefer not to know the true evidence boundary
Contradictions
✕Several high-profile NMN human studies have shown mixed results on aging endpoints
Tracking Metrics
→New NMN human RCT publications
→Inbound longevity product questions
→Longevity Atlas sprint conversion rate
Judgment History (1 entries)
Node Createdv0.12026-06-200 → 72low → medium
Node created. Inbound question (cq_002) directly maps to this node.
Ready to generate an Intel File for this node?
Attach 2 more evidence record(s) before generating.